CB-103 is primarily investigated for its potential in cancer therapy, particularly in targeting pathways involved in tumor growth and survival. It shows promise in inhibiting specific protein interactions that are crucial for the proliferation of cancer cells, making it a candidate for treating certain types of cancers that are resistant to conventional therapies. Research is ongoing to explore its efficacy and safety in clinical settings, with a focus on its ability to disrupt oncogenic signaling networks. Additionally, it is being studied for its potential to enhance the effectiveness of other cancer treatments when used in combination therapies.